Professor Tae-Yoon Park earned his B.S. (2005), M.S. (2007), and Ph.D. (2013) in Biotechnology from Yonsei University, where he developed therapeutic platforms involving T-cell differentiation, transcription factor modulation, and protein transduction technologies. He subsequently served as a Postdoctoral Research Fellow at the Yonsei University Institute of Life Science and Biotechnology and the BK21 Plus Program (2013–2017), establishing his expertise in immunology and cell-based therapeutics. From 2017 to 2020, he worked as a Research Associate in the Molecular Neurobiology Laboratory at McLean Hospital, Harvard Medical School, and later as an Instructor and Assistant Neuroscientist (2020–2025), contributing centrally to the world’s first clinical transplantation of autologous iPSC-derived dopamine neurons (NEJM, 2020) and the development of TREG co-transplantation technology (Nature, 2023), both of which redefined the therapeutic landscape of Parkinson’s disease. In 2025, he joined The Catholic University of Korea as an Assistant Professor in the Department of Medical Life Sciences, where he leads research on needle trauma–induced neuroinflammation, immune–cell microenvironmental modulation, and next-generation cell therapy platforms. His publication record exceeds a cumulative IF of 300, with papers in NEJM, Nature, Cell Stem Cell, Cell Research, and other leading journals. Professor Park is an active member of major scientific societies including AAI, ISSCR, ISCT, and SfN, and is the recipient of multiple honors such as the ISCT ESP Rookie of the Year, SfN Trainee Professional Development Award, AKN Junior Research Scientist Award, and the KSSCR/K-BioX Young Scientist Award(1st winner). He also holds multiple domestic and international patents related to transcription factor modulation and therapeutic ginsenoside derivatives, and continues to pursue clinically translatable strategies in immune-integrated regenerative medicine.